Investor sentiment toward domestic pharmaceutical stocks related to obesity treatments weakened after news that obesity drugs prescribed overseas through official channels would be allowed to be brought into the country for personal use. This appears to reflect concerns that price competition from overseas products could affect sales of new domestic products. However, as the actual impact on prescriptions and sales remains to be seen, investors should consider both price competitiveness and the business outlook for each product.


If considering buying the dip during a share price correction, it is important to review earnings forecasts and determine the investment size and funding plan. A stock-backed loan may be an option for obtaining additional investment funds, depending on the terms applicable to the account and eligible stocks. Allocating funds with financing costs and repayment capacity in mind can help investors follow planned dollar-cost averaging purchases while monitoring sales trends.


HiStockLoan has maintained its No. 1 position in the industry for 22 years and offers a range of stock financing products, including products with annual interest rates in the 5% range. It can be used not only to obtain new investment funds but also to refinance credit and unsettled stock transactions. As a result, it is drawing attention as an option for investors seeking to reduce their funding burden while securing investment opportunities.

Domestic Obesity Drug Stocks Retreat After Approval of Overseas Imports, but Bargain Buying Persists View original image

[Visit the industry-leading HiStockLoan: https://www.hisl.co.kr]


Meanwhile, interest in stock-backed loans continues to grow. Investors looking to make the most of a rare investment opportunity are turning to these loans to access more funds for stock purchases.


Another advantage of a stock-backed loan is that even if investors using unsettled or credit transactions face the risk of forced liquidation following a sharp share price drop, they can switch over easily without providing additional collateral or selling stocks and wait for a rebound.


HiStockLoan: Additional investment funds and refinancing of credit and unsettled transactions at an industry-low annual interest rate in the 5% range

HiStockLoan has launched a securities-linked credit product available at an industry-low annual interest rate in the 5% range, allowing all investors to use a stock-backed loan without undue burden. The product can be used both to buy stocks and to refinance unsettled or credit transactions with securities firms. Investors can borrow up to four times their equity, including their own capital, with no differentiation based on credit rating. Investors using alternative trading system NXT can also use the product. Recently, securities firms have shortened the term for new credit loans from 180 days to 90 days. Investors concerned about the length of time they can use funds may therefore also consider refinancing through a stock-backed loan.


Investors who want to learn about HiStockLoan's range of customized products can contact the customer service center at 1566-5113 for convenient consultations with a specialist at any time, 24 hours a day, regardless of whether they qualify for a loan.


- Industry-low annual interest rate in the 5% range

- ETF trading available

- No. 1 in market share for 22 consecutive years; Korea First Brand Award winner for 17 consecutive years

- Real-time repayment of unsettled and credit transactions with securities firms

- Trading through alternative trading system NXT available

- Reliable consultation quality guarantee program

* HiStockLoan customer service center: 1566-5113

Visit: https://www.hisl.co.kr


SK Square, SIMMTECH, Hanjin KAL Preferred, Hanmi Pharmaceutical, Hanwha Aerospace



※ This content does not reflect the editorial direction of The Asia Business Daily, and all responsibility rests with the information provider.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing